98%
921
2 minutes
20
Rare earth elements (REEs) are crucial in modern technology and essential for the transition to a low-carbon economy. Despite the rising global demand for nano-neodymium oxide (NPs-NdO), a rare earth nanoparticle, comprehensive studies on its neurotoxic effects are limited. This study aims to elucidate the chronic neurotoxic effects of NPs-NdO and explore their molecular mechanisms. Our findings show that NPs-NdO accumulation in zebrafish brains impairs embryonic neural development, acute exposure to 120 h post-fertilization (hpf) - 7 days post-fertilization (dpf), causing behavioral alterations such as reduced movement distance, average velocity, and increased manic frequency and thigmotaxis. Chronic exposure to NPs-NdO until 42 dpf exhibited similar anxiety-like behavioral abnormalities. Histopathological analysis revealed developmental delays in brain formation, significant tectal ventricle (TeV) and midbrain ventricle atrophy, deterioration of the periventricular gray zone (PGZ), and decreased Nissl body density in exposed larvae. Continued exposure to 100 dpf resulted in further reductions in brain width, length, and area, and decreased Nissl body density. RNA-Seq analysis identified the retinol metabolic pathway as a critical target of NPs-NdO exposure, with validation confirming differential gene expression related to this pathway. Disrupted retinol metabolism may underlie NPs-NdO-induced neurotoxicity, exacerbated by reduced dopaminergic neurons. Additionally, cellular experiments showed that NPs-NdO inhibit neurite growth. This study advances our understanding of NPs-NdO toxicity mechanisms and provides a framework for investigating the neurotoxic effects of similar compounds.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jhazmat.2025.138879 | DOI Listing |
Eur J Haematol
September 2025
Department of Hematology-Oncology, Texas Tech University Health Sciences Center, Lubbock, Texas, USA.
B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapies have revolutionized the approach and management of relapsed/refractory multiple myeloma (RRMM), and as of 2025, idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel) are the only BCMA-targeted CAR T-cell therapies approved by the FDA. Exceptional responses were demonstrated for heavily pretreated patients in the KarMMa-1 trial, reporting a 73% overall response rate (ORR) and 98% in the CARTITUDE-1 trial. Furthermore, both therapies show a significant improvement in progression-free survival (PFS) compared to standard regimens when administered in earlier lines.
View Article and Find Full Text PDFBlood Cell Ther
August 2025
Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Science, Fukuoka, Japan.
Background: Chimeric antigen receptor T-cell (CAR-T) therapy has transformed the treatment landscape for relapsed or refractory non-Hodgkin lymphoma, achieving a 5-year overall survival rate of 40-50%. However, relapse remains a major challenge, especially due to CD19-negative clones. Epcoritamab, a bispecific antibody targeting CD20 and CD3, offers a potential solution for post-CAR-T relapse; however, clinical data in this setting remain limited, particularly in Japan.
View Article and Find Full Text PDFCurr Alzheimer Res
September 2025
Department of Life Science and Bioinformatics, Assam University, Silchar, 788011, Assam, India.
Introduction: Arsenic, a metalloid, is well associated as a risk factor for the development and progression of neurodegenerative diseases, including Alzheimer's Disease (AD), which is characterized by impairment in cognition. However, specific effects of arsenic on Acetylcholinesterase (AChE) activity and inflammatory markers in different brain regions, as well as its impact on behaviour, are not yet fully understood.
Methods: Arsenic was administered (20 mg/kg by gavage for 4 weeks) to male and female mice, and its effects on behaviour were assessed by using the object recognition memory test and lightdark box test.
Am J Psychiatry
September 2025
Department of Psychiatry, School of Medicine, Yale University, New Haven.
This review examines ketamine's neurotoxic potential across preclinical and clinical studies. The authors synthesized data from preclinical models, then integrated findings from human clinical trials of esketamine and observational studies in recreational users. Animal studies have found that repeated or high-dose subanesthetic ketamine administration results in consistent excitotoxic neuronal damage and lasting cognitive deficits, especially in perinatal animals.
View Article and Find Full Text PDFAm J Hematol
September 2025
Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, California, USA.
Blinatumomab is approved for the treatment of relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL). Studies have correlated pre-blinatumomab high disease burden (HDB) [> 50% bone marrow blasts (BMB)] with lower response rates and increased risk for toxicities, including cytokine release syndrome (CRS) and neurotoxicity (NT). While the administration of pre-blinatumomab cytoreductive therapy is an appealing approach, larger studies validating the beneficial effect of this strategy in patients with HDB are lacking.
View Article and Find Full Text PDF